Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiations – Cash of $72.00 per share and 0.83 Shares of Valeant stock – Contingent Value Right for DARPin of up to $25.00 per Share in Value – Pershing Square agrees to forego all cash and accept 100% of its consideration in Valeant stock using an exchange ratio determined based on yesterday’s closing stock prices of AGN and VRX – Pershing Square will receive $20.75 per share less consideration than other AGN shareholders, providing substantially more value and cash for other AGN stockholders – Proposal contingent on good faith negotiations – Conference Call and webcast to discuss proposal on Monday, June 2, 2014 at 8:00 am ET PR Newswire LAVAL, Quebec, May 30, 2014 LAVAL, Quebec , May 30, 2014 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE: VRX) (TSX: VRX) today announced that it is making an offer for Allergan, Inc. […]